Western long-term accuracy of serum pepsinogen-based gastric cancer screening

Western long-term accuracy of serum pepsinogen-based gastric cancer screening BackgroundEven though mass gastric cancer screening is controversial in Western countries, diverse strategies have been proposed in intermediate-risk to high-risk areas.AimThe aim of this study was to determine the long-term accuracy of the pepsinogen test (PG) for early diagnosis of gastric cancer.Participants and methodsA cohort of inhabitants from the Northern part of Portugal, aged between 40 and 74 years (n=5913), subjected to the PG test (PGI≤70 ng/ml and PGI/PGII≤3), were followed up between November 2006 and December 2015. The diagnosis of gastric cancer was determined through linkage to the population-based registry of cancer [North Region Cancer Registry of Portugal (RORENO)].ResultsTwenty-six gastric cancers were diagnosed (0.4%): nine (4%) among individuals ‘positive’ for the PG test (n=225) and 15 (0.3%) among those who were ‘negative’ (n=5688) [hazard ratio=12.7; 95% confidence interval (CI): 5.6–28.6]. Individuals with a ‘negative PG test’ had a 3-year risk of gastric cancer of 0.1%, representing a sensitivity of 35% (95% CI: 17–56%), globally, and of 58% (95% CI: 28–85%) at 3 years follow-up. The median survival rate in both groups was over 24 months.ConclusionThe PG test was found to be suboptimal as a screening test and, if used (before upper gastrointestinal endoscopy), it is mandatory to repeat it after 3 years. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Gastroenterology & Hepatology Wolters Kluwer Health

Loading next page...
 
/lp/wolters_kluwer/western-long-term-accuracy-of-serum-pepsinogen-based-gastric-cancer-Uo1PtK7eAg
Publisher
Wolters Kluwer Health
Copyright
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
0954-691X
eISSN
1473-5687
D.O.I.
10.1097/MEG.0000000000001040
Publisher site
See Article on Publisher Site

Abstract

BackgroundEven though mass gastric cancer screening is controversial in Western countries, diverse strategies have been proposed in intermediate-risk to high-risk areas.AimThe aim of this study was to determine the long-term accuracy of the pepsinogen test (PG) for early diagnosis of gastric cancer.Participants and methodsA cohort of inhabitants from the Northern part of Portugal, aged between 40 and 74 years (n=5913), subjected to the PG test (PGI≤70 ng/ml and PGI/PGII≤3), were followed up between November 2006 and December 2015. The diagnosis of gastric cancer was determined through linkage to the population-based registry of cancer [North Region Cancer Registry of Portugal (RORENO)].ResultsTwenty-six gastric cancers were diagnosed (0.4%): nine (4%) among individuals ‘positive’ for the PG test (n=225) and 15 (0.3%) among those who were ‘negative’ (n=5688) [hazard ratio=12.7; 95% confidence interval (CI): 5.6–28.6]. Individuals with a ‘negative PG test’ had a 3-year risk of gastric cancer of 0.1%, representing a sensitivity of 35% (95% CI: 17–56%), globally, and of 58% (95% CI: 28–85%) at 3 years follow-up. The median survival rate in both groups was over 24 months.ConclusionThe PG test was found to be suboptimal as a screening test and, if used (before upper gastrointestinal endoscopy), it is mandatory to repeat it after 3 years.

Journal

European Journal of Gastroenterology & HepatologyWolters Kluwer Health

Published: Mar 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off